-+ 0.00%
-+ 0.00%
-+ 0.00%

Duopharma Biotech Q3 profit after tax rises 24% year over year to RM 27.98 million; Q3 revenue falls 6% to RM 210.05 million year over year

PUBT·11/17/2026 04:35:11
Listen to the news
Duopharma Biotech Q3 profit after tax rises 24% year over year to RM 27.98 million; Q3 revenue falls 6% to RM 210.05 million year over year
  • Duopharma Biotech’s third-quarter profit after tax rose 24% year over year to RM 27.98 million.
  • Revenue fell 6% year over year to RM 210.05 million in the quarter ended September 30, 2026.
  • Nine-month profit after tax climbed 29% to RM 88.56 million on a favorable product mix and lower input costs.
  • The group secured three Ministry of Health insulin supply contracts totaling RM 225.85 million during 2026, expanding its portfolio.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Duopharma Biotech Bhd published the original content used to generate this news brief via Bursa Malaysia (KLSE) (Ref. ID: 3724871) on November 17, 2026, and is solely responsible for the information contained therein.